Schrodinger (NASDAQ:SDGR – Get Free Report) and Health In Tech (NASDAQ:HIT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Risk and Volatility
Schrodinger has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Health In Tech has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500.
Valuation & Earnings
This table compares Schrodinger and Health In Tech”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Schrodinger | $255.87 million | 8.43 | -$103.26 million | ($0.79) | -37.01 |
| Health In Tech | $32.83 million | 0.85 | -$4.59 million | ($0.07) | -6.09 |
Health In Tech has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Health In Tech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Schrodinger and Health In Tech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Schrodinger | -22.02% | -18.12% | -9.07% |
| Health In Tech | N/A | N/A | N/A |
Institutional and Insider Ownership
79.0% of Schrodinger shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 71.0% of Health In Tech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Schrodinger and Health In Tech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
| Health In Tech | 1 | 0 | 1 | 1 | 2.67 |
Schrodinger currently has a consensus target price of $26.67, indicating a potential downside of 8.78%. Health In Tech has a consensus target price of $3.50, indicating a potential upside of 721.60%. Given Health In Tech’s stronger consensus rating and higher probable upside, analysts plainly believe Health In Tech is more favorable than Schrodinger.
Summary
Health In Tech beats Schrodinger on 11 of the 15 factors compared between the two stocks.
About Schrodinger
Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.
About Health In Tech
Health In Tech, Inc. is a U.S.-based insurance technology company that provides a digital platform for the self-funded health benefits market. Its technology is designed to connect employers, insurance brokers, third-party administrators and stop-loss carriers through a streamlined process for evaluating and administering health benefit plans. The company’s platform supports functions including plan quoting, comparison and enrollment, with the goal of simplifying interactions among participants in the employer-sponsored health insurance ecosystem.
Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.
